Nuveen LLC Makes New $2.64 Million Investment in Liquidia Technologies, Inc. $LQDA

Key Points

• Nuveen LLC has acquired a new stake in Liquidia Technologies, purchasing 179,085 shares valued at approximately $2.64 million, representing about 0.21% of the company.
• Liquidia Technologies reported a 141.5% year-over-year increase in revenue, although it missed earnings expectations with a reported EPS of ($0.49).
• Several institutional investors have recently shifted their positions in Liquidia Technologies, with 64.54% of the stock now held by institutional investors and hedge funds.

Nuveen LLC bought a new position in Liquidia Technologies, Inc. (NASDAQ:LQDA - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 179,085 shares of the company's stock, valued at approximately $2,642,000. Nuveen LLC owned approximately 0.21% of Liquidia Technologies at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Hurley Capital LLC purchased a new stake in Liquidia Technologies in the 1st quarter worth approximately $32,000. GAMMA Investing LLC increased its holdings in Liquidia Technologies by 65.6% in the 1st quarter. GAMMA Investing LLC now owns 2,961 shares of the company's stock worth $44,000 after acquiring an additional 1,173 shares in the last quarter. D. E. Shaw & Co. Inc. purchased a new stake in Liquidia Technologies in the 4th quarter worth approximately $142,000. Aigen Investment Management LP purchased a new stake in Liquidia Technologies in the 1st quarter worth approximately $151,000. Finally, Bayesian Capital Management LP purchased a new stake in Liquidia Technologies in the 4th quarter worth approximately $163,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

Liquidia Technologies Price Performance

LQDA stock traded up $0.64 during trading on Wednesday, hitting $29.22. 2,897,860 shares of the company's stock traded hands, compared to its average volume of 2,924,484. Liquidia Technologies, Inc. has a 52 week low of $8.75 and a 52 week high of $29.94. The company has a debt-to-equity ratio of 9.84, a quick ratio of 2.41 and a current ratio of 2.49. The business has a fifty day simple moving average of $19.79 and a 200 day simple moving average of $16.61. The stock has a market capitalization of $2.52 billion, a price-to-earnings ratio of -17.19 and a beta of 0.22.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.06). Liquidia Technologies had a negative net margin of 732.17% and a negative return on equity of 232.96%. The business had revenue of $8.84 million for the quarter, compared to the consensus estimate of $3.90 million. The company's quarterly revenue was up 141.5% compared to the same quarter last year. As a group, research analysts expect that Liquidia Technologies, Inc. will post -1.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on LQDA shares. Wall Street Zen raised shares of Liquidia Technologies from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Oppenheimer set a $13.00 price objective on shares of Liquidia Technologies and gave the company an "underperform" rating in a report on Monday, May 19th. Wells Fargo & Company increased their price objective on shares of Liquidia Technologies from $25.00 to $31.00 and gave the company an "overweight" rating in a report on Wednesday, August 13th. Needham & Company LLC increased their price objective on shares of Liquidia Technologies from $32.00 to $36.00 and gave the company a "buy" rating in a report on Tuesday, August 12th. Finally, HC Wainwright increased their price objective on shares of Liquidia Technologies from $29.00 to $35.00 and gave the company a "buy" rating in a report on Wednesday, May 28th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $32.11.

Insider Buying and Selling at Liquidia Technologies

In other Liquidia Technologies news, Director Paul B. Manning sold 328,268 shares of the stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $28.78, for a total transaction of $9,447,553.04. Following the completion of the transaction, the director owned 430,828 shares in the company, valued at $12,399,229.84. This trade represents a 43.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Michael Kaseta sold 30,000 shares of the stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $20.00, for a total transaction of $600,000.00. Following the transaction, the chief financial officer owned 376,412 shares of the company's stock, valued at $7,528,240. This trade represents a 7.38% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 828,073 shares of company stock valued at $22,294,240 over the last ninety days. Corporate insiders own 30.10% of the company's stock.

About Liquidia Technologies

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).